KalVista Pharmaceuticals is a global biopharmaceutical company focused on developing oral therapies for rare diseases. Its lead product, EKTERLY (sebetralstat), a novel oral plasma kallikrein inhibitor, received FDA approval in July 2025 for on-demand treatment of acute hereditary angioedema (HAE) attacks in patients aged 12 and older. The company also pursues Factor XIIa inhibitors and seeks to in-license or acquire complementary pipeline assets.
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-07-10 | 2025-04-30 | 0000950170-25-095011 | EDGAR | 67K words |
| 2024-07-11 | 2024-04-30 | 0000950170-24-082965 | EDGAR | 61K words |
| 2023-07-10 | 2023-04-30 | 0000950170-23-032298 | EDGAR | 55K words |
| 2022-07-07 | 2022-04-30 | 0000950170-22-012521 | EDGAR | — |
| 2021-07-13 | 2021-04-30 | 0001564590-21-036441 | EDGAR | — |
| 2020-07-01 | 2020-04-30 | 0001564590-20-031501 | EDGAR | — |
| 2019-07-16 | 2019-04-30 | 0001564590-19-025009 | EDGAR | — |
| 2018-07-30 | 2018-04-30 | 0001564590-18-017915 | EDGAR | — |
| 2017-07-27 | 2017-04-30 | 0001564590-17-014286 | EDGAR | — |
| 2016-03-30 | 2015-12-31 | 0001564590-16-015646 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-274442 | EDGAR | 18K words |
| 2025-09-11 | 2025-07-31 | 0001193125-25-200757 | EDGAR | 14K words |
| 2025-03-12 | 2025-01-31 | 0000950170-25-037995 | EDGAR | 18K words |
| 2024-12-05 | 2024-10-31 | 0000950170-24-133673 | EDGAR | 15K words |
| 2024-09-05 | 2024-07-31 | 0000950170-24-103981 | EDGAR | 13K words |
| 2024-03-11 | 2024-01-31 | 0000950170-24-029314 | EDGAR | 16K words |
| 2023-12-07 | 2023-10-31 | 0000950170-23-068801 | EDGAR | 15K words |
| 2023-09-07 | 2023-07-31 | 0000950170-23-047008 | EDGAR | 13K words |
| 2023-03-09 | 2023-01-31 | 0000950170-23-007020 | EDGAR | 15K words |
| 2022-12-08 | 2022-10-31 | 0000950170-22-026230 | EDGAR | 15K words |
| 2022-09-08 | 2022-07-31 | 0000950170-22-018239 | EDGAR | — |
| 2022-03-10 | 2022-01-31 | 0000950170-22-003361 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001193125-26-122784 | EDGAR | 2K words |
| 2026-01-08 | 0001193125-26-007801 | EDGAR | 2K words |
| 2025-11-10 | 0001193125-25-274405 | EDGAR | 2K words |
| 2025-10-06 | 0001193125-25-230906 | EDGAR | 1K words |
| 2025-10-02 | 0001193125-25-227478 | EDGAR | 1K words |
| 2025-09-29 | 0001193125-25-223262 | EDGAR | 1K words |
| 2025-09-11 | 0001193125-25-200742 | EDGAR | 2K words |
| 2025-08-21 | 0001193125-25-185382 | EDGAR | 1K words |
| 2025-07-10 | 0001193125-25-157382 | EDGAR | 2K words |
| 2025-07-07 | 0001193125-25-155885 | EDGAR | 2K words |
193 total filings indexed. 161 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001348911 |
| Ticker | KALV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.kalvista.com |
| Listed | 2015-04-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KALV (~200 tokens, structured JSON with cryptographic provenance)